Impact of Rapid Detection of MRSA

N/AWithdrawnNCT02027389

Mayo Clinic

Overview

The objective of this study is to evaluate the impact of the Alere\™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.

Study Type

OBSERVATIONAL

Conditions

Staphylococcus Aureus Infections

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: 1. Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures (both control and intervention periods) 2. Above, with rapid PBP2a testing (intervention period only). Exclusion criteria: 1. Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms in the culture). 2. Patients who have not provided MN authorization to use their medical records for research. 3. Patients who have had the FilmArray Blood culture identification diagnostic test performed on an index S. aureus blood culture. 4. Patients who have had a sterile source S. aureus culture within the prior 30 days.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Time (hours) to optimal antimicrobial therapy for patients with MSSA and MRSA infections in the pre-intervention and post-intervention periods

Time frame: within first 7 days of culture result

Secondary Outcomes

Time (in hours) to identification of MRSA.

Time frame: within first 3 days of culture result

Vancomycin days of therapy following S. aureus culture result

Time frame: during the 2 weeks following culture result

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.